BofA lowered the firm's price target on Buenaventura to $12 from $14 and keeps a Neutral rating on the shares. The company's Q1 results were largely uneventful with a reiteration of R&D program timelines, and the firm maintains its view that shares could be range-bound until the company can address its financing overhang amidst 2026 catalysts, the analyst tells investors in a research note.
